Ligand snaps up fellow biotech royalty aggregator Xoma for $739M

Ligand Pharmaceuticals will acquire Xoma Royalty for $39 per share, valuing the deal at roughly $739 million and implying a 14% premium to Xoma’s 30-day average price. The transaction adds more than 120 biopharma assets, including 14 late-stage programs, and Ligand lifted its 2026 revenue forecast to $270 million-$310 million from $245 million-$285 million. Xoma holders will also receive a CVR tied to 75% of net proceeds from certain pending litigation against J&J’s Janssen unit over Tremfya commercialization.

Analysis

This is effectively a portfolio-quality transaction, not just a control premium event. Ligand is buying duration: it converts a lumpy, externally sourced royalty book into a larger, more diversified stream with better financing optionality, while XOMA holders are being paid for both the asset base and the embedded litigation lottery ticket. The market is likely still underestimating how much this improves Ligand’s “funding cost” profile over the next 12-24 months, because a bigger recurring royalty base should widen access to lower-cost capital and make future acquisitions more accretive.

The second-order winner is the broader royalty-aggregation model, which now has a live precedent for strategic consolidation at a premium to trading levels. That matters for smaller, illiquid royalty names because it raises the probability of takeover-driven repricing even if operating fundamentals remain unchanged. The main loser is J&J via Janssen: the CVR structure keeps the litigation overhang alive post-close, and the existence of a contingent payout effectively monetizes uncertainty that may force a settlement conversation sooner than expected.

For ZVRA, the implication is subtle but important: Ligand’s ownership of the royalty stream should reinforce commercial focus on the underlying asset, but it also means the public-market read-through is now a cleaner proxy for royalty value rather than full-company equity upside. The bigger risk to the trade is regulatory or litigation slippage that delays close into 4Q; that would compress the arbitrage spread and could temporarily pressure XOMA as deal certainty gets re-priced. Conversely, if the CVR is judged economically meaningful, XOMA may trade with a wider-than-usual convexity to any positive litigation headlines over the next several months.

Key Decisions for Investors

• Long XOMA / short LGND as a constrained spread trade into close only if XOMA trades at a material discount to implied deal value; target 2-4% annualized with a hard stop if regulatory or litigation risk widens the spread beyond historical biotech-deal norms.
• Own LGND on pullbacks for 6-12 months: the acquisition should improve portfolio diversification and financing power; upside is multiple expansion if the market starts capitalizing the larger royalty stream at a lower discount rate.
• Buy short-dated calls or call spreads on XOMA only if liquidity remains sufficient and the implied break discount is attractive; this is a convex arb only if litigation headlines create temporary dislocations.
• Reduce or avoid outright JNJ exposure if you think the CVR increases settlement pressure around Tremfya; the risk is not core earnings, but an incremental legal reserve or nuisance payment that could emerge over the next 1-2 quarters.
• Watch smaller royalty-aggregation peers for sympathy re-rating; a basket long in the sector on acquisition optionality could outperform over the next 3-6 months if the market starts pricing a consolidation wave.